Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CTNM

Contineum Therapeutics

CTNM Rare disease Lead: Phase 2 1 Biotech Distilled article ↓ 15 filings & releases ↓ Cash $75.2M (Sep 30, 2026) ↓ 1 verdict ↓
NeurologyRespiratory Small Molecule

Market cap $374M 39.3M shares (vendor count, Nov 7, 2026) × $9.52 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-05

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. WuXi AppTec / BIOSECURE FDADec 18, 2026WuXi AppTec / BIOSECURE FDA, Dec 18, 2026, material
  2. Admilparant (BMS) ALOFT-PPF toplineEarly 2027Admilparant (BMS) ALOFT-PPF topline, Early 2027, material
  3. Inhaled treprostinil United Therapeutics sNDA2027Inhaled treprostinil United Therapeutics sNDA, 2027, notable
  4. PIPE-791 IPF enrollment done2027PIPE-791 IPF enrollment done, 2027, notable
  5. Admilparant (BMS) ALOFT-IPF full dataMay 2027Admilparant (BMS) ALOFT-IPF full data, May 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$75.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$169M Sep 30, 2026
Operating cash flow
−$11.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$245M cash, runway mid-2029 per the deep dive of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Contineum Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-11-05 Watch Contineum Therapeutics (CTNM) - Scientific Deep Dive for PIPE-791 and Pipeline Products Well-engineered LPA1 antagonist with validated class and funded Phase 2, but PIPE-791 has never been tested in IPF patients, its differentiation claim met a bad data point in Bristol's 120 mg arm, the FDA's blood-pressure concern has kept PROPEL-IPF out of the US, and all patents are pending.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (15)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)